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Protein misfolding is linked to different neurodegenerative disorders like Alzheimer’s disease, polyglutamine, and prion
diseases. We investigated the cytotoxic effects of aberrant conformers of the prion protein (PrP) and show that toxicity is
specifically linked to misfolding of PrP in the cytosolic compartment and involves binding of PrP to the anti-apoptotic
protein Bcl-2. PrP targeted to different cellular compartments, including the cytosol, nucleus, and mitochondria, adopted
a misfolded and partially proteinase K–resistant conformation. However, only in the cytosol did the accumulation of
misfolded PrP induce apoptosis. Apoptotic cell death was also induced by two pathogenic mutants of PrP, which are
partially localized in the cytosol. A mechanistic analysis revealed that the toxic potential is linked to an internal domain
of PrP (amino acids 115–156) and involves coaggregation of cytosolic PrP with Bcl-2. Increased expression of the
chaperones Hsp70 and Hsp40 prevented the formation of PrP/Bcl-2 coaggregates and interfered with PrP-induced
apoptosis. Our study reveals a compartment-specific toxicity of PrP misfolding that involves coaggregation of Bcl-2 and
indicates a protective role of molecular chaperones.
INTRODUCTION
Prion diseases are a group of transmissible neurodegenera-
tive disorders including Creutzfeldt-Jakob disease (CJD) and
Gerstmann-Sträussler-Scheinker syndrome (GSS) in hu-
mans, scrapie in sheep and goat, bovine spongiform enceph-
alopathy (BSE) in cattle and chronic wasting disease (CWD)
in free-ranging deer. A hallmark of prion diseases is the
conversion of the cellular prion protein PrPC into PrPSc, a
misfolded and proteinase K (PK)-resistant isoform, which is
the main component of infectious prions (reviewed in
Weissmann et al., 1996; Prusiner et al., 1998; Collinge, 2001;
Chesebro, 2003; Aguzzi and Polymenidou, 2004).
In the majority of prion diseases neurodegeneration is
tightly linked to the propagation of infectious prions. How-
ever, transgenic mouse models revealed that misfolding or
mistargeting of PrPC can induce neuronal cell death in the
absence of infectious prions. Vice versa, propagation of in-
fectious prions was observed without inducing neuronal cell
death, but only when PrPC is not expressed in neurons
(reviewed in Winklhofer and Tatzelt, 2006). Moreover, neu-
ronal expression of a secreted PrP mutant devoid of the
glycosylphosphatidylinositol (GPI) anchor sustains propa-
gation of infectious prions in the absence of clinical symp-
toms (Chesebro et al., 2005).
The biogenesis of PrPC is characterized by a series of co-
and posttranslational modifications (reviewed in Tatzelt and
Winklhofer, 2004). It involves import of the nascent chain into
the endoplasmic reticulum (ER) and the attachment of two
N-linked core glycans and a GPI anchor. After processing of
the glycans into complex structures in the Golgi compartment,
PrPC is targeted to the outer leaflet of the plasma membrane.
Several studies indicated that PrP can acquire a neurotoxic
potential when its import into the ER is partially or completely
compromised. Lingappa and coworkers demonstrated that
during import into the ER, PrP can attain two different trans-
membrane topologies termed CtmPrP and NtmPrP (Yost et al.,
1990). Interestingly, increased synthesis of CtmPrP has been
shown to coincide with progressive neurodegeneration both
in GSS syndrome patients with an A117V mutation and in
transgenic mice carrying a triple mutation within the hydro-
phobic domain (AV3; Hegde et al., 1998; Stewart et al., 2005).
A different transgenic mouse model revealed that prevent-
ing the import of PrP into the ER leads to the formation of a
neurotoxic PrP species. Mice expressing a PrP mutant with a
deleted N-terminal ER targeting signal (cytoPrP) acquired
severe ataxia due to cerebellar degeneration and gliosis (Ma
et al., 2002). Earlier results already indicated that both wild-
type PrP and a PrP mutant associated with an inherited
prion disease in humans can be found in the cytosol and are
subjected to proteasomal degradation (Ma and Lindquist,
2001; Yedidia et al., 2001). Cytotoxic effects of cytoPrP were
also observed in some cell culture models (Ma et al., 2002;
Rane et al., 2004), whereas in other studies expression of
cytoPrP seemed not to interfere with cellular viability
(Roucou et al., 2003; Fioriti et al., 2005). Support for a toxic
potential of cytosolically localized PrP was also obtained
in a yeast model. During posttranslational targeting of
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PrP to the ER, PrP was missorted to the cytosol and
interfered with yeast growth (Heller et al., 2003).
So far, mutations within the N-terminal signal sequence of
PrP, which could affect the efficiency of ER import, have not
been identified in patients suffering from prion diseases. The
analysis of PrP-W145Stop, however, revealed that a pathogenic
PrP mutant linked to GSS syndrome, is found in the cytosolic
and nuclear compartment (Zanusso et al., 1999). Further studies
including a different pathogenic mutant, PrP-Q160Stop, cor-
roborated these findings and revealed that information in the
C-terminal domain of PrP is necessary and sufficient for import
into the endoplasmic reticulum (Heske et al., 2004).
In this study, we directed PrP to different cellular com-
partments and analyzed the impact on cell viability. Al-
though in all compartments analyzed PrP adopted a deter-
gent-insoluble, partially PK-resistant conformation, only
cytosolic PrP interfered with cell viability and induced ap-
optosis. The apoptotic potential of cytosolic PrP was linked
to an internal domain of PrP, comprising the hydrophobic
domain and helix 1, and correlated with the binding of Bcl-2
to misfolded PrP. Binding of Bcl-2 to PrP, as well as apopto-
sis, could be prevented by the increased expression of Hsp70
and its cochaperone Hsp40, indicating a protective role of
chaperones in PrP-induced toxicity.
MATERIALS AND METHODS
Antibodies and Reagents
The following antibodies were used: anti-PrP 3F4 monoclonal antibody (mAb;
Kascsak et al., 1987), anti-PrP 3B5 mAb (Krasemann et al., 1996), anti-PrP
antiserum A7 (Winklhofer et al., 2003a), anti-ACTIVE caspase-3 polyclonal
antibody (pAb; Promega, Madison, WI), anti-Hsp40 pAb (Stressgen, Victoria,
British Columbia, Canada), anti-Bcl-2 mouse mAb (BD Biosciences, San Di-
ego, CA), anti-GAPDH mouse mAb (6C5; Calbiochem, La Jolla, CA), Cy3-
conjugated anti-mouse IgG antibody and Cy3-conjugated anti-rabbit IgG
antibody (Dianova, Hamburg, Germany), anti-FLAG M2 mAb (Sigma, De-
isenhofen, Germany), anti-FLAG pAb (rabbit, Sigma), anti-GFP mAb (Roche,
Indianapolis, IN). The following reagents were used: MG132 (Calbiochem),
PK (Roche), and staurosporin and valinomycin (Sigma). The mounting me-
dium Mowiol (Calbiochem) was supplemented with 4,6-diamidino-2-phe-
nylindole (DAPI, Sigma).
Plasmids
The following constructs were described previously: wtPrP, PrPGPI
(Winklhofer et al., 2003c), Q160Stop, W145Stop, cytoPrP (Heske et al., 2004),
and EYFP-Hsp70, Hsp40 (Kim et al., 2002; Winklhofer et al., 2003b). All amino
acid numbers refer to the mouse PrP sequence (GenBank accession number
M18070). For the generation of PrP targeted to the nucleus (nucPrP) or
mitochondria (mtPrP), the authentic ER signal sequence of PrPC was replaced
by the nuclear localization signal of SV40 large T antigen (MDPKKKRKV) or
the mitochondrial signal sequence of subunit 1 of the ubiquinol cytochrome C
reductase complex (MAASAVCRAACSGTQVLLRTRRSPALLRPALRGTATFA),
respectively. Human XIAP with a N-terminal FLAG-tag (MDYKDDDDK)
was described earlier (Bartke et al., 2004). FLAG-Bcl-2 was generated by
fusing a FLAG-tag (DYKDDDDK) to the C-terminus of human Bcl-2
(GenBank accession number AAA51813). As a mitochondrial marker
pEYFP-Mito vector (Clontech, Heidelberg, Germany) was used.
Figure 1. Specific targeting of PrP to different cellular compart-
ments. (A) Schematic presentation of the PrP mutants analyzed.
ER-SS, ER signal sequence; OR, octarepeat; HD, hydrophobic do-
main; , alpha helix; , beta strand; GPI-SS, GPI anchor signal
sequence; mt-SS, mitochondrial signal sequence; NLS, nuclear lo-
calization signal. All mutants are devoid of the GPI-SS (aa 231–253).
(B) SH-SY5Y cells were transiently transfected with plasmids en-
coding wild-type PrP or the mutant prion proteins and analyzed by
indirect immunofluorescence using the anti-PrP mAb 3F4 (PrP).
Nuclei were stained with DAPI. (C) Confocal images of SH-SY5Y
cells coexpressing mtPrP and EYFP-Mito, which is specifically tar-
geted to mitochondria. Indirect immunofluorescence was per-
formed using the anti-PrP mAb 3F4. (D) mtPrP is imported into
mitochondria in vitro. mtPrP cDNA was translated in vitro and the
radiolabeled mtPrP (input) was incubated with isolated mitochon-
dria for 20 min at 25°C. To one sample valinomycin was added
(valinomycin ) to inhibit mitochondrial import. After import, each
sample was divided into two aliquots. From one aliquot the mito-
chondria were pelleted directly and boiled in sample buffer (PK ).
The other aliquot was first treated with PK (500 g/ml; PK ). All
samples were analyzed by SDS-PAGE and autoradiography. P,
precursor with the uncleaved mitochondrial targeting signal se-
quence; M, mature protein. Bars, 15 m.
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Cell Culture, Transfection, Proteasomal Inhibition, and
Proteinase K Digestion
SH-SY5Y cells were cultivated as described earlier (Winklhofer et al., 2003c).
Cells cultivated on a 3.5-cm cell culture dish (Nunc, Wiesbaden-Biebrich,
Germany) were transfected with a total of 2 g DNA by a liposome-mediated
method using LipofectAMINE Plus reagent (Invitrogen, Karlsruhe, Germany)
according to the manufacturer’s instructions. To keep the amount of trans-
fected cytoPrP constant, a plasmid expressing EYFP or ECFP under the same
promoter was added to a total of 2 g DNA. The proteasomal inhibitor
MG132 was dissolved in dimethyl sulfoxide, added to the cell culture me-
dium (30 M), and incubated for 3 h at 37°C. For proteolysis experiments,
cells were lysed in cold buffer A (0.5% Triton X-100, 0.5% sodium deoxy-
cholate [DOC] in phosphate-buffered saline [PBS]) and incubated for 30 min
at 4°C with PK at the concentrations indicated. The reaction was terminated
by addition of Pefabloc SC (Roche) and boiling in Laemmli sample buffer.
Residual PrP was detected by Western blotting.
Detergent Solubility Assay, Western Blotting, and Sucrose
Step Gradient
As described earlier (Tatzelt et al., 1996), cells were washed twice with cold
saline buffer (PBS), scraped off the plate, pelleted by centrifugation, and lysed
in cold buffer A. After centrifugation the detergent-soluble and -insoluble
fractions were analyzed by Western blotting. To examine the secretion of PrP
into the cell culture supernatant, cells were cultivated in serum-free medium
for 3 h at 37°C. Medium was collected, and proteins precipitated with trichlo-
roacetic acid (TCA) and then analyzed by Western blotting. SDS-PAGE and
Western blotting were described previously (Winklhofer and Tatzelt, 2000).
For sucrose step gradient analysis, cells were lysed in 150 l gradient buffer
containing 0.1% Triton X-100, 25 mM Tris-HCl (pH 7.5), 100 mM NaCl, 5 mM
MgCl2, and 5% glycerol. The gradient was performed as described earlier
(Henn et al., 2005). Ten fractions were collected from the top of the gradient.
The proteins were precipitated by TCA and analyzed by Western blotting.
Scrapie Infection and Preparation of Brain Extracts
Intracerebral infections of C57B/6 mice with scrapie-strain 139A were carried
out as previously described (Schultz et al., 2004). Brain extracts were prepared
in buffer A (10% w/vol) and fractionated by centrifugation into the detergent-
soluble and -insoluble fraction as described above. For PK digestion the whole
lysate was adjusted to 1% Sarkosyl and incubated with PK (50 g/ml) for 1 h
at 37°C. The reaction was terminated by addition of Pefabloc SC and boiling
in Laemmli sample buffer. Residual PrP was detected by Western blotting
using the anti-PrP antiserum A7.
In Vitro Translation and Mitochondrial Import Assay
The in vitro translation was carried out by using the TNT T7 Quick
Coupled Transcription/Translation System (Promega) by following the
manufacturer’s instructions. After translation the samples were used for the
mitochondrial import assay as described earlier (Stan et al., 2003). Protein
import in yeast mitochondria was performed in SI buffer (3% BSA [w/vol], 0.5
M sorbitol, 50 mM HEPES-KOH, 80 mM KCl, 10 mM MgAc, 2 mM KH2PO4,
2.5 mM EDTA, 2.5 mM MnCl2, 2 mM ATP, 2 mM NADH, pH 7.2). Protease
treatment of mitochondria was performed by incubation with PK for 15 min
on ice, followed by the addition of 1 mM phenylmethylsulfonyl fluoride for 5
min as described before. Products were analyzed by SDS-PAGE. Gels were
impregnated with Amplify (GE Healthcare, Waukesha, WI) and exposed to
film.
Metabolic Labeling and Immunoprecipitation
Cells were starved for 30 min in methionine-free minimum Eagle’s medium
(Invitrogen) and subsequently labeled for 45 min with 300 Ci/ml Promix
[L-35S] in vitro cell label mix (Amersham Biosciences, Braunschweig, Ger-
many; 37 TBq/mmol) in methionine-free minimum Eagle’s medium (pulse).
When indicated, the proteasomal inhibitor MG132 was present during star-
vation, labeling, and chase periods (30 M final concentration). For the chase,
labeling medium was removed, cells were washed twice and then incubated
in complete medium for 30 min at 37°C. Immunoprecipitation of PrP was
performed as described earlier (Winklhofer et al., 2003c). For the coimmuno-
precipitation experiments, low-detergent buffer (0.1% Triton X-100 in PBS)
was used for cell lysis and incubation with the antibody. Proteins present in
the immunopellet were released by boiling in buffer B (Triton X-100, DOC,
Sarkosyl, 0.5% each in PBS) and subjected to a second immunoprecipitation
under nonnative conditions.
Co-pullup Experiments
Cells were lysed in low-detergent buffer (0.1% Triton X-100 in PBS) and
incubated for 16 h with anti-FLAG M2 mAb at 4°C. To extract FLAG-tagged
Bcl-2 proteins, the cell lysate was incubated with magnetic anti-mouse IgG-
DYNAbeads (Invitrogen) for 2 h and exposed to a magnetic field for 2 min to
pull up bound immunocomplexes. Unbound material was removed and
analyzed by Western blotting. After washing, the immunocomplexes were
dissolved by boiling in Laemmli sample buffer and analyzed for bound
cytoPrP by Western blotting, using the anti-PrP antibody A7. Anti-FLAG M2
mAb was used to detect the Bcl-2 constructs.
Indirect Immunofluorescence and Apoptosis Assay
For indirect immunofluorescence experiments, SH-SY5Y cells were grown on
glass coverslips, fixed with 3% PFA for 20 min, and permeabilized with 0.2%
Triton X-100 for 10 min at room temperature. The primary antibody was
incubated for 45 min at 37°C in PBS containing 1% BSA. After extensive
washing with cold PBS, an incubation with the Cy3-conjugated secondary
antibody followed at 37°C for 30 min. For detection of apoptosis, cells were
fixed and permeabilized as described above. Blocking of the cells was per-
formed with 5% horse serum and 0.1% Tween 20 in PBS for 1 h at room
temperature. Cells were then incubated with anti-ACTIVE caspase-3 antibody
overnight at 4°C, followed by Cy3-conjugated secondary antibody for 1 h at
Figure 2. PrP mutants adopt a misfolded and partially PK-resistant conformation. (A–C) SH-SY5Y cells were transiently transfected with
wild-type PrPC or the indicated PrP mutants and analyzed 24 h after transfection. (A) Cells were lysed in cold buffer A and fractionated by
centrifugation. PrP present in the detergent-soluble (S) and -insoluble (P) fractions was analyzed by Western blotting using the mAb 3F4. In
case of PrPGPI, secretion of PrP was analyzed in addition. Cells were cultivated for 3 h in serum-free medium at 37°C, and PrP present in
the medium was then analyzed by Western blotting (PrPGPI, M). (B) Total cell lysates were treated with increasing concentrations of PK
as indicated at 4°C for 30 min. Residual PrP was detected by Western blotting. Molecular size markers are indicated as bars on the left side
of the panels. (C) Cells were lysed in gradient buffer (0.5% Triton X-100) and placed on top of a 30–40% sucrose step gradient. After
ultracentrifugation 10 fractions were collected from the top of the gradient and analyzed by Western blotting using the anti-PrP antibody 3F4.
Precursor and mature form of mtPrP are indicated by * and **, respectively.
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room temperature. Cells were mounted onto glass slides and examined by
fluorescence microscopy using a Zeiss Axiovert 200M microscope (Carl Zeiss,
Oberkochen, Germany). To analyze the apoptotic potential of the various PrP
constructs, the number of activated caspase-3–positive cells out of 1000 trans-
fected cells was determined. All quantifications were based on at least three
independent experiments. Confocal images were obtained on a Leica DM
IRE2 confocal microscope (Leica, Heidelberg, Germany) and evaluated with
the Leica confocal software version 2.6.1.
Statistical Analysis
Data were expressed as means  SE. All experiments were performed in
duplicates and repeated at least three times. Statistical analysis among groups
was performed using student’s t test. P-values are as follows: *p  0.01, **p 
0.001, and ***p  0.0001.
RESULTS
PrP Directed to Different Cellular Compartments Adopts
a Misfolded Conformation
Previous studies in transgenic mice revealed that misfold-
ing of PrP in the cytosol can induce neurodegeneration
(Ma et al., 2002). The neurotoxic PrP conformer present in
the cytosol (cytoPrP) is quite distinct from infectious
PrPSc. CytoPrP adopts a misfolded and partially PK-resis-
tant conformation; however, it lacks posttranslational
modifications, like the GPI anchor and N-linked carbohy-
drates; moreover, it does not seem to be infectious. In the
present study we addressed the question of whether mis-
folding of PrP is cytotoxic per se or whether PrP-induced
toxicity is linked to the cellular compartment in which PrP
adopts a misfolded conformation.
To achieve subcellular targeting of PrP to different com-
partments, including the nucleus, cytosol, mitochondria and
ER, the following constructs were generated: nucPrP with
the nuclear localization signal (NLS) of SV40 T antigen,
mtPrP with the mitochondrial signal sequence of ubiquinol
cytochrome C reductase complex subunit 1, and cytoPrP
lacking the authentic ER signal sequence (Figure 1A). To
include a PrP conformer that misfolds in the secretory path-
way, we used a mutant that contains the N-terminal ER-
Figure 3. PrP misfolding in the cytosol in-
duces apoptosis. (A) PrP localized in the cytosol
and nucleus is degraded by the proteasome.
Transiently transfected SH-SY5Y cells were la-
beled for 45 min with [35S]methionine in the
presence (MG132 ) or absence (MG132 ) of
the proteasome inhibitor MG132 (30 M). PrP
was then analyzed by immunoprecipitation us-
ing the mAb 3F4. (B and C) Cytosolic PrP in-
duces apoptosis after inhibition of the protea-
some. SH-SY5Y cells were cotransfected with
EYFP and PrP mutants as indicated. Twenty-
four hours after transfection cells were incu-
bated with MG132 (30 M) at 37°C for 3 h, fixed,
permeabilized, and analyzed by indirect immu-
nofluorescence. Activation of caspase-3 was de-
tected by using the anti-ACTIVE caspase-3 pAb.
Nuclei were stained with DAPI. (C) Quantifica-
tion of apoptosis. One thousand transfected cells
were counted in at least three independent ex-
periments. Shown is the percentage of apoptotic
cells among the transfected cells. **p  0.001
compared with all other PrP mutants and the
EYFP control. Bars, 40 m.
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targeting signal but lacks the C-terminal GPI signal se-
quence (designated PrPGPI). Targeting to and import into
the ER of PrPGPI is efficient, but in the secretory pathway
PrPGPI spontaneously adopts a misfolded conformation
and is secreted (Rogers et al., 1993; Blochberger et al., 1997;
Winklhofer et al., 2003c).
First, we analyzed the subcellular localization of the dif-
ferent PrP constructs. Indirect immunofluorescence analysis
of transiently transfected SH-SY5Y cells revealed that the
targeting sequences efficiently directed PrP to the respective
cellular compartments (Figure 1B). Targeting of PrP into
mitochondria was further confirmed using an in vitro im-
port assay and colocalization analysis (Figure 1, C and D). In
addition, import of PrPGPI into the ER was corroborated
by the detection of secreted PrPGPI in the cell culture
supernatant (Figure 2A). Notably, SH-SY5Y cells do not
express significant levels of endogenous PrPC (unpublished
data). Thus, only the heterologously expressed PrP con-
structs are detected in our assays.
To compare the conformation of PrP in different cellular
compartments, we made use of three biochemical assays:
solubility in detergent buffer, sensitivity to a limited PK
digestion, and a sedimentation analysis on a sucrose step
gradient. In contrast to wild-type PrPC, all PrP mutants,
including PrPGPI, were mainly insoluble in detergent
buffer (Figure 2A) and showed an increased resistance to
proteolytic digestion (Figure 2B). In addition, all mutants
formed aggregates. Protein extracts of transiently trans-
Figure 4. Pathogenic mutants are missorted
to the cytosol and induce apoptosis. (A) Sche-
matic presentation of two pathogenic PrP mu-
tants linked to inherited prion diseases in hu-
mans. Two versions of each mutant were
generated, one version with the authentic N-
terminal ER signal sequence (ER-SS) and one
for cytosolic expression by deleting the ER-SS
(cyto). (B–D) Transiently transfected SH-SY5Y
cells expressing the pathogenic mutants either
with the ER signal sequence (ER) or without
(cyto) were cultivated for 45 min (B) or 3 h (C)
in the presence or in the absence of the pro-
teasome inhibitor MG132. PrP was analyzed
by immunoprecipitation (B) and indirect im-
munofluorescence (C) as described in Figure 3.
(D) Quantification of apoptosis induced by the
pathogenic PrP mutants. Apoptosis was de-
tected by indirect immunofluorescence using
the anti-ACTIVE caspase-3 pAb. Shown is the
percentage of apoptotic cells among the trans-
fected cells. *p 0.01, **p  0.001, and ***p 
0.0001 compared with EYFP-transfected cells.
Bars, 15 m.
A. S. Rambold et al.
Molecular Biology of the Cell3360
fected cells were applied on top of a sucrose step gradient.
After centrifugation all mutant PrP constructs were found in
the bottom fraction, whereas wild-type PrPC remained in the
top fractions (Figure 2C).
These experiments established that PrP can efficiently be
targeted to different cellular compartments. The biochemical
properties of the PrP mutants present in the nucleus, cytosol,
mitochondria and ER are similar and indicate the formation
of misfolded and aggregated conformers.
Apoptosis Is Selectively Induced by Misfolding of PrP in
the Cytosol
The Western blot analysis indicated that the steady state
level of cytoPrP was considerably lower than that of the
other PrP mutants (Figure 2A). The most plausible expla-
nation for this phenomenon was proteasomal degradation
of cytoPrP. Indeed, after proteasomal inhibition by
MG132 (3 h, 30 M) the relative levels of cytoPrP and
Figure 5. CytoPrP binds to and induces aggregation of Bcl-2. (A and B) CytoPrP interacts with Bcl-2 in SH-SY5Y cells. (A) For coimmunopre-
cipitation experiments (lanes 3 and 4) SH-SY5Y cells were transfected with cytoPrP and FLAG-tagged Bcl-2 (lane 4) or with Bcl-2 only (lane 3). Cells
were metabolically labeled for 45 min in the presence of MG132 (30 M) and lysed in low-detergent buffer. After immunoprecipitation of PrP under
native conditions with the anti-PrP antibody 3B5 (1. IP, PrP), proteins released from the immunopellet were subjected to a second immunopre-
cipitation under nonnative conditions using an anti-FLAG antibody (2. IP, FLAG). As a control, PrP and Bcl-2 were analyzed by immunopre-
cipitation under nonnative conditions (lanes 1 and 2). (B) Transfected cells were analyzed by indirect immunofluorescence using the anti-FLAG pAb
and the PrP-specific 3F4 mAb by confocal microscopy. (C) CytoPrP induces aggregation of Bcl-2 but not of Bcl-2202–219. Cells were cotransfected
with FLAG-tagged Bcl-2 or Bcl-2202–219 and either EYFP, cytoPrP, or mtPrP. Total cell lysates were prepared in gradient buffer, loaded on a
30–40% sucrose step gradient, and centrifuged at 200,000  g for 90 min at 4°C. Ten fractions were collected from the top of the gradient, proteins
were precipitated by TCA and immunoblotted for FLAG-Bcl-2 and PrP, respectively. A long exposure image was used for FLAG-Bcl-2  cytoPrP
(PrP) to show that cytoPrP also localizes to the upper fractions of the gradient. (D) CytoPrP interacts with endogenous Bcl-2. SH-SY5Y cells were
transfected with either EYFP or cytoPrP. CytoPrP-induced aggregation of endogenous Bcl-2 was analyzed by centrifugation through a 30–40%
sucrose step gradient as described in C. (E) Brain extracts of terminally scrapie-ill (sc) and control (co) mice were prepared and fractionated by
centrifugation into the detergent-soluble (S) and -insoluble fraction (P). Samples were analyzed by Western blotting for PrP, Bcl-2, and GAPDH,
respectively. In addition, one sample was digested with proteinase K to specifically detect PrPSc (PrP, PK). (F) Overexpression of Bcl-2 and
Bcl-2202–219 interferes with cytoPrP-induced apoptosis. Cells were transfected with cytoPrP alone or cotransfected with cytoPrP and Bcl-2 or
Bcl-2202–219. Apoptotic cells were identified by indirect immunofluorescence using the anti-ACTIVE caspase-3 pAb. Shown is the percentage of
apoptotic cells among the transfected cells. **p  0.001 compared with cytoPrP-expressing cells. Bars, 15 m.
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nucPrP were significantly increased, whereas the protea-
some inhibitor had no significant effect on the relative
amount of PrP imported into the ER or mitochondria
(Figure 3A).
Next, we analyzed possible adverse effects of misfolded
PrP on cellular viability. To identify cells undergoing
apoptosis, transiently transfected neuroblastoma cells
were analyzed by indirect immunofluorescence using an
antibody specific for activated caspase-3. The specificity
of the antibody was confirmed in control experiments
with cells subjected to increasing concentrations of stau-
rosporine, a known inducer of apoptosis. Under physio-
logical culture conditions, expression of cytoPrP slightly
increased the number of apoptotic cells, whereas expres-
sion of the other PrP mutants did not result in caspase-3
activation above control conditions, i.e., expression of
wild-type PrPC or cytosolic EYFP (Figure 3C, MG132).
The cytotoxic effect of cytoPrP was significantly enhanced
in cells transiently exposed to the proteasomal inhibitor
MG132. Importantly, transient treatment with MG132 nei-
ther induced apoptosis in cells expressing PrPC or cyto-
solic EYFP nor in cells harboring misfolded PrP in the
mitochondria, the nucleus, or the ER (Figure 3, B and C,
MG132). The enhanced toxicity of cytoPrP in MG132-
treated cells correlated with the increased amount of cy-
toPrP in these cells (Figure 3A, MG132). However, it is
important to note that the increased level of cytoPrP is not
sufficient to explain its cytotoxic effect, because the rela-
tive amount of cytoPrP never exceeded that of PrPGPI,
mtPrP, or nucPrP (Figure 3A and unpublished data). In
this context it is interesting to note that a small fraction of
mtPrP contained an uncleaved signal peptide, but did not
induce apoptosis. It is possible that this precursor, al-
though localized in the cytosol, is already associated with
the mitochondria import machinery or bound to cytosolic
proteins, like Hsp70, which are involved in targeting to
and import into mitochondria.
Thus, a toxic potential of misfolded PrP was specifically
linked to its cytosolic localization. Cellular viability was
not affected by misfolded PrP present in other cellular
compartments, be it the ER, the mitochondria, or the
nucleus.
Pathogenic Mutations Linked to Inherited Prion Diseases
in Humans Are Mistargeted to the Cytosol and Induce
Apoptosis
The above experiments demonstrated that mistargeting of
PrP to the cytosol can effectively induce apoptosis. The
question remained whether such a mistargeting could play a
role in the pathogenesis of human prion diseases. Previous
studies indicated that upon proteasomal degradation wild-
type and mutant D177N PrP accumulates in the cytosol (Ma
and Lindquist, 2001; Yedidia et al., 2001). Similarly, we and
others showed that Q160Stop and W145Stop (Figure 4A),
two pathogenic PrP mutants characterized by large C-termi-
nal deletions, are partially present in the cytosol and are
subjected to proteasomal degradation (Zanusso et al., 1999;
Heske et al., 2004). This phenomenon is illustrated by an
immunoprecipitation analysis of transiently transfected SH-
SY5Y cells cultivated for 3 h in the presence of MG132 before
the sample preparation (Figure 4B, MG132). In addition,
an indirect immunofluorescence analysis indicated a signif-
icant increase of cytosolically localized Q160Stop and
W145Stop after transient proteasomal inhibition (Figure 4C).
Two scenarios are conceivable to explain this phenomenon.
Either the C-terminal deletion mutants are subjected to ER-
associated protein degradation (ERAD) or their import into
the ER is partially compromised.
Consequently, we tested whether these pathogenic mu-
tants can interfere with cellular viability. Indeed, expres-
sion of Q160Stop and W145Stop induced apoptosis simi-
larly to cytoPrP (Figure 4D). To specifically analyze the
cytosolic fraction of these mutants, we generated cytosolic
versions of these mutants, which lack the N-terminal ER
signal sequence and thus are exclusively targeted to the
cytosol (Figure 4A). Apoptosis was significantly increased
after the expression of cytoQ160Stop and cytoW145Stop,
indicating that the cytosolic fractions seem to be respon-
sible for the toxic effects of Q160Stop and W145Stop
(Figure 4D).
Figure 6. CytoPrP neither interacts with nor induces
aggregation of XIAP. (A) CytoPrP does not induce ag-
gregation of XIAP. SH-SY5Y cells were transfected with
XIAP and XIAP/cytoPrP, respectively. The sedimenta-
tion profile of XIAP and cytoPrP was analyzed by a
sucrose step gradient as described in Figure 5. (B) XIAP
does not interact with cytoPrP. SH-SY5Y cells express-
ing XIAP alone or in combination with cytoPrP were
analyzed by coimmunoprecipitation experiments as de-
scribed in Figure 5 (lanes 3 and 4). After a first immu-
noprecipitation under native conditions using the anti-
PrP antibody 3B5, proteins in the immunopellet were
analyzed by a second immunoprecipitation under non-
native conditions using an anti-XIAP antibody (lanes 3
and 4). As a control, PrP and XIAP were analyzed by
immunoprecipitation under nonnative conditions from
cells expressing either PrP or XIAP (lanes 1 and 2). (C)
Coexpression of Bcl-2 or XIAP does not interfere with
expression of cytoPrP. SH-SY5Y cells were cotransfected
with cytoPrP/ECFP, cytoPrP/Bcl-2, or cytoPrP/XIAP.
The cells were lysed in cold buffer A and analyzed by
immunoblotting using the indicated antibodies.
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These findings revealed that two pathogenic PrP mutants,
linked to inherited prion diseases in humans, are missorted
to the cytosol and induce apoptosis. In addition, these ex-
periments indicated that the distal region of the globular
C-terminal domain (aa 146–231) is dispensable for the toxic
effect of cytosolic PrP.
Figure 7. The toxic potential of cytoPrP re-
sides within the proximal part of the C-termi-
nal domain. (A) Schematic representation of
cytosolic PrP deletion mutants. (B) SH-SY5Y
cells were cotransfected with EYFP and the
PrP mutants as indicated. Twenty-four hours
after transfection, the cells were cultivated for
additional 3 h in the presence or absence of
the proteasome inhibitor MG132 (30 M). Ap-
optotic cells were identified by indirect immu-
nofluorescence using the anti-ACTIVE caspase-3
pAb. One thousand transfected cells were
counted in at least three independent experi-
ments. Shown is the percentage of apoptotic
cells among the transfected cells. **p  0.001
compared with cytoPrP-expressing cells. (C)
Transiently transfected SH-SY5Y cells ex-
pressing the PrP mutants were cultivated 3 h
in the presence or absence of the proteasome
inhibitor MG132. Cells were lysed in cold
buffer A and fractionated by centrifugation.
PrP was analyzed by Western blotting using the
mAb 3F4. (D) SH-SY5Y cells were transfected
with FLAG-Bcl-2/cytoPrP, FLAG-Bcl-2202–
219/cytoPrP, and FLAG-Bcl-2/cyto116–173 as
indicated. Cells were lysed in low-detergent
buffer and incubated with anti-FLAG M2 mAb.
The cell lysate was subjected to pull up exper-
iments using magnetic beads coupled with
anti-mouse IgG. Bound immunocomplexes
(pull up) and unbound material (unbound)
were analyzed for cytoPrP by immunoblot-
ting using the 3F4 mAb. (E) Cells were co-
transfected with FLAG-tagged Bcl-2 and PrP
constructs as indicated. Total cell lysates were
prepared in gradient buffer, loaded on a 30–
40% sucrose step gradient, and centrifuged at
200,000  g for 90 min at 4°C. Ten fractions
were collected from the top of the gradient,
proteins were precipitated by TCA, and im-
munoblotted for FLAG-Bcl-2 and PrP.
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Cytosolic PrP Binds to and Coaggregates with Bcl-2
Previous in vitro studies showed that PrP can interact with
the anti-apoptotic protein Bcl-2 and mapped the interaction
site to the carboxy terminus of Bcl-2 (aa 200–236; Kurschner
and Morgan, 1995, 1996). Consequently, we tested whether
an interaction of cytosolic PrP with Bcl-2 occurs in our cell
culture model. First, we analyzed a possible interaction of
PrP with Bcl-2 by coimmunoprecipitation experiments.
Transiently transfected cells expressing both cytoPrP and
FLAG-tagged Bcl-2 were metabolically labeled with [35S]me-
thionine. The cells were then lysed in low-detergent buffer,
and PrP was immunoprecipitated with the mAb 3B5 under
native conditions. Proteins bound to the immunopellet were
subsequently released by boiling in detergent buffer B, and
a second immunoprecipitation was performed using the
anti-FLAG antibody to isolate FLAG-tagged Bcl-2. Bcl-2 co-
purified under these conditions, indicating that cytoPrP in-
teracts with Bcl-2 in neuronal cells (Figure 5A, lane 4). Im-
portantly, the same procedure did not purify Bcl-2 from cells
that do not express cytoPrP (Figure 5A, lane 3) or from cells
expressing wtPrP (unpublished data). Moreover, Bcl-2202–
219, a mutant with a deletion in the PrP-interacting domain
(Kurschner and Morgan, 1996), did not interact with cytoPrP
either (see Figure 7D). In addition, we demonstrated colo-
calization of cytoPrP with Bcl-2 in intact cells by indirect
immunofluorescence (Figure 5B).
To analyze whether the interaction of Bcl-2 with PrP has
an impact on the biochemical properties of Bcl-2, cells were
cotransfected with FLAG-tagged Bcl-2 and either EYFP or
cytoPrP or mtPrP. Protein extracts were prepared in gradi-
ent buffer and layered on top of a sucrose step gradient.
After centrifugation 10 fractions were collected and ana-
lyzed by Western blotting. In the absence of cytoPrP, Bcl-2
remained in the top fractions (Figure 5C, EYFP). In cells
coexpressing cytoPrP, however, Bcl-2 cosedimented with
cytoPrP and was also found in the bottom fraction (Figure
5C, cytoPrP). Notably, no sedimentation of Bcl-2 was ob-
served in the presence of mitochondrial PrP (Figure 5C,
mtPrP). Similarly, FLAG-Bcl-2202–219 was not recruited
into cytoPrP aggregates (Figure 5C, FLAG-Bcl-2202–219).
Coaggregation was not restricted to overexpressed FLAG-
Bcl-2 as cytoPrP also induced aggregation of endogenous
Bcl-2 (Figure 5D). In this context it is important to note that
the cells coexpressing Bcl-2 and cytoPrP were vital and did
not undergo apoptosis, due to the overexpression of Bcl-2.
Assuming that the aggregation of Bcl-2 could be of patho-
physiological relevance to prion diseases, we analyzed Bcl-2
in brain extracts prepared from terminally scrapie-ill mice.
Figure 8. Cytosolic chaperones interact with cytoPrP.
(A) The cytosolic chaperone Hsp70 interacts with cyto-
PrP in SH-SY5Y cells. For coimmunoprecipitations, SH-
SY5Y cells were cotransfected with cytoPrP and YFP-
Hsp70 (lane 4) or with cytoPrP only (lane 3). Cells were
metabolically labeled for 45 min in the presence of
MG132 (30 M) and lysed in low-detergent buffer. After
an immunoprecipitation of YFP-Hsp70 under native
conditions with the anti-GFP antibody (1. IP, GFP)
proteins in the immunopellet were subjected to a second
immunoprecipitation under nonnative conditions using
the anti-PrP mAb 3F4 (2. IP, PrP). As a control, expres-
sion of PrP and YFP-Hsp70 was analyzed by immuno-
precipitation under nonnative conditions (lanes 1 and
2). (B and C) The cytosolic chaperones Hsp70 and Hsp40
coaggregate with cytoPrP. Cells were cotransfected with
YFP-Hsp70/Hsp40 or YFP-Hsp70/Hsp40/cytoPrP. (B)
Total cell lysates were prepared in gradient buffer,
loaded on a 30–40% sucrose step gradient and centri-
fuged at 200,000  g for 90 min at 4°C. Ten fractions
were collected from the top of the gradient, proteins
were precipitated by TCA and immunoblotted for YFP-
Hsp70, Hsp40, and PrP, respectively. (C) Confocal im-
ages of SH-SY5Y cells coexpressing Hsp70/Hsp40 and
cytoPrP. Indirect immunofluorescence was performed
using the anti-PrP mAb 3F4. YFP-Hsp70 is shown in
green, and nuclei are stained with DAPI. Bars, 15 m.
A. S. Rambold et al.
Molecular Biology of the Cell3364
In contrast to the uninfected control, Bcl-2 was predomi-
nantly detergent-insoluble in the scrapie-diseased brain
(Figure 5E, sc). Of note, infection of the brain with scrapie-
prions did not cause protein aggregation in general. Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH), a cytosolic
protein, was found in the detergent-soluble fraction in both
the control and scrapie-infected brain samples (Figure 5E).
If the interaction of PrP with Bcl-2 correlates with the toxic
potential of cytoPrP, coexpression of Bcl-2 should alleviate
the apoptotic effects of cytoPrP. To test this possibility, ap-
optosis was analyzed in cells expressing both Bcl-2 and
cytoPrP. Indeed, the coexpression of both Bcl-2 and Bcl-
2202–219 interfered with cytoPrP-induced apoptosis (Fig-
ure 5F).
In response to apoptotic signals, the release of mitochon-
drial factors such as cytochrome c leads to the activation of
caspase-9 and further on to that of caspase-3. XIAP, a known
inhibitor of caspase-9 and -3, suppressed cytoPrP-induced
apoptosis when overexpressed in cultured cells. Nonethe-
less, cytoPrP neither interacted with XIAP in coimmunopre-
cipitation experiments, nor did it induce the aggregation of
XIAP (Figure 6, A and B). This further indicates that cytoPrP
does not randomly coaggregate with anti-apoptotic proteins.
Notably, the relative levels of cytoPrP were not decreased by
the coexpression of Bcl-2 or XIAP (Figure 6C).
The Toxic Potential of cytoPrP Resides within the
Proximal Part of the Globular Domain, including the
Hydrophobic Domain and Helix 1
To investigate whether the cytotoxic potential of cytoPrP is
linked to a specific domain, we created several deletion
mutants of cytoPrP (Figure 7A). Interestingly, all mutants
devoid of the proximal part of the C-terminal globular do-
main (aa 116–156), comprising the hydrophobic domain and
helix 1, did not induce apoptosis. Furthermore, expression of
the internal domain, cyto108–173, induced apoptosis, al-
though less efficiently than cytoPrP (Figure 7B). Importantly,
differences in the apoptotic potential of the PrP mutants
were not due to differences in the expression levels, because
the relative amount of the nontoxic mutant cyto116–173
was comparable to that of cytoPrP (Figure 7C). To provide
experimental evidence for a direct association of aggregated
Bcl-2 with misfolded PrP, pullup experiments were per-
formed. In this approach Bcl-2 was immunopurified simi-
larly to coimmunoprecipitation described above; however,
to avoid centrifugation, magnetic anti-mouse IgG-DYNA-
beads were used. The immunocomplexes were pulled up by
a magnetic field and analyzed by Western blotting. Again,
cyto-PrP copurified under these conditions. However, nei-
ther was the nontoxic mutant cyto116–173 pulled up by
Bcl-2 nor was cytoPrP bound by Bcl2202–219 (Figure 7D).
Further support for the assumption that the formation of
Bcl-2/cytoPrP aggregates is linked to apoptosis would be
provided if the expression of the nontoxic mutant cyto116–
173 does not lead to the aggregation of Bcl-2. Indeed, the
sucrose gradient analysis revealed that in contrast to cytoPrP
or cyto108–173, cyto116–173 did not induce aggregation of
Bcl-2. Notably, the internal deletion did not restore folding
of cyto116–173 because the mutant was still found in the
bottom fractions of the sucrose gradient (Figure 7E).
Cytosolic Chaperones Bind to cytoPrP and Interfere with
PrP-induced Apoptosis and the Formation of PrP/Bcl-2
Coaggregates
The biochemical analysis of cytoPrP revealed a nonnative,
misfolded conformation that should be recognized by mo-
lecular chaperones. Indeed, in an earlier study indirect im-
munofluorescence experiments revealed colocalization of
Figure 9. Cytosolic chaperones interfere with cyto-
PrP-induced apoptosis and aggregation of Bcl-2. (A)
Overexpression of Hsp70 and Hsp40 interferes with
PrP-induced apoptosis. SH-SY5Y cells were trans-
fected as indicated and treated with MG132 (30
M) for 3 h. Apoptotic cells were identified by
indirect immunofluorescence using the anti-AC-
TIVE caspase-3 pAb. The percentage of apoptotic
cells among the transfected cells is shown. **p 
0.001 compared with cytoPrP-expressing cells. (B)
Coexpression of Bcl-2 or Hsp70/40/Bcl-2 does not
interfere with the expression of cytoPrP. To keep the
amount of transfected cytoPrP constant, a plasmid
expressing EYFP under the same promoter was
added to a total of 2 g DNA. Cells were lysed in
cold buffer A and analyzed by immunoblotting us-
ing the indicated antibodies. (C) Overexpression of
Hsp70 and Hsp40 interferes with PrP-induced ag-
gregation of Bcl-2. SH-SY5Y cells were transiently
cotransfected with cytoPrP/Bcl-2 and cytoPrP/Bcl-2/
YFP-Hsp70/Hsp40, respectively. Whole cell lysates
were analyzed on a 30–40% sucrose step gradient.
Fractions were collected and immunoblotted against
YFP-Hsp70 and FLAG-Bcl-2.
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cytoPrP with Hsp70 (Ma and Lindquist, 2001). We therefore
analyzed a possible interaction of cytoPrP with the cytosolic
chaperones Hsp70 and Hsp40. For coimmunoprecipitation
experiments we expressed cytoPrP together with YFP-Hsp70
and Hsp40. Previous experiments established that the chap-
erone activity of Hsp70 is not compromised by the YFP tag
(Kim et al., 2002). After a first immunoprecipitation with an
anti-GFP antibody under native conditions, the immunopel-
let was boiled in detergent buffer B and PrP was immuno-
precipitated with the monoclonal anti-PrP antibody 3F4. PrP
copurified under these conditions, but only in the presence
of Hsp70 (Figure 8A, lane 4). A sucrose step gradient pro-
vided further evidence that cytoPrP is bound by the cytoso-
lic chaperones Hsp70 and Hsp40. In the absence of cytoPrP,
Hsp70 as well as Hsp40 were exclusively found in the top
fractions. When cytoPrP was coexpressed, the chaperones
were found in the bottom fraction together with cytoPrP
(Figure 8B). Interestingly, the chaperones obviously affected
the biochemical properties of cytoPrP. In cells overexpress-
ing Hsp70 and Hsp40, a portion of cytoPrP was found in the
top fraction of the sucrose gradient (Figure 8B, compare to
Figure 2C). Finally, we performed an indirect immunofluo-
rescence analysis to visualize colocalization of cytoPrP and
EYFP-Hsp70 (Figure 8C).
In a next step we wanted to determine whether the inter-
action of cytoPrP with Hsp70 and Hsp40 modulates the
cytotoxic potential of cytoPrP. Indeed, the caspase-3 assay
revealed that the coexpression of Hsp70 and Hsp40 inter-
fered with cytoPrP-induced apoptosis. In the presence of
Hsp70 and Hsp40 the number of apoptotic cells were re-
duced to background levels (Figure 9A). Importantly, the
relative amount of cytoPrP was not reduced by the coex-
pression of Hsp70 and Hsp40 (Figure 9B).
As shown above, Bcl-2 binds to and coaggregates with
cytoPrP (Figure 5). To test the possibility that coexpression
of chaperones modulates this interaction, we biochemically
analyzed Bcl-2 in cells expressing Hsp70 and Hsp40 in ad-
dition to cytoPrP. As expected, Bcl-2 aggregation was ob-
served in cells expressing cytoPrP; however, coexpression of
Hsp70 and Hsp40 interfered with cytoPrP-induced aggrega-
tion of Bcl-2 (Figure 9C).
In summary, these results indicate that misfolded cytoPrP
is recognized and bound by Hsp70 and Hsp40. As a conse-
quence, the cytotoxic potential of cytoPrP and the formation
of PrP/Bcl2 coaggregates are reduced.
DISCUSSION
In this study, we analyzed the biochemical properties and
cytotoxic potential of PrP targeted to different cellular com-
partments. Although PrP adopted a misfolded conformation
in all compartments analyzed, i.e., the cytosol, nucleus, ER,
and mitochondria, apoptosis only occurred when misfolded
PrP accumulated in the cytosol. Our study also revealed that
the toxic potential of cytosolic PrP (cytoPrP) correlated with
its binding to Bcl-2, which is an essential component of the
intracellular apoptotic signaling pathways (Danial and Kors-
meyer, 2004).
Biogenesis of PrPC is characterized by a series of co- and
posttranslational modifications (reviewed in Tatzelt and
Winklhofer, 2004). Among those, addition of the GPI anchor
seems to be of particular importance. Initial experiments in
cell culture revealed that a mutant devoid of the C-terminal
GPI anchor signal sequence (PrPGPI) is imported into the
ER but remains mainly unglycosylated, spontaneously
adopts a misfolded conformation and is efficiently secreted
(Rogers et al., 1993; Blochberger et al., 1997; Winklhofer et al.,
2003c). The phenotype of anchorless PrP described in cul-
tured cells was recently confirmed in transgenic mice. No-
tably, expression of PrPGPI did not result in clinical symp-
toms, at least not during the life span of mice (Chesebro et
al., 2005). Biochemically, PrPGPI (named GPI()PrPsen in
the mouse study) is similar to the PrP mutant targeted to the
cytosol (cytoPrP): both mutants lack the C-terminal signal
sequence, are unglycosylated, and adopt a misfolded con-
formation. However, transgenic mice expressing cytoPrP
acquired severe ataxia with cerebellar degeneration (Ma et
al., 2002). Our cell culture model recapitulates the observa-
tions in transgenic mice: cytoPrP efficiently induced apopto-
sis, whereas expression of PrPGPI had no obvious effect on
cellular viability. How can the obvious difference in the
neurotoxic potential of PrPGPI and cytoPrP be explained?
Possibly, the neurotoxic potential is linked to a specific
conformation, and the conformation of PrPGPI and cyto-
PrP may be different. Alternatively, the cellular compart-
ment in which PrP misfolding occurs is crucial. Our study
provides experimental evidence that the cellular compart-
ment might play a significant role. PrP mutants targeted to
the cytosol, nucleus, ER, or mitochondria showed similar
biochemical features, yet apoptosis was exclusively induced
by cytosolic PrP.
Although the pathophysiological role of cytoPrP might be
restricted to a subset of prion diseases, there are several
ways to generate of cytoPrP in vivo. It was recently shown
that the signal sequence of PrP is insufficient for complete
protein translocation into the ER, giving rise to a nontrans-
located PrP fraction in the cytosol (Rane et al., 2004). In line
with these results, the pathogenic mutants Q160Stop and
W145Stop are partially mislocalized in the cytosol (Zanusso
et al., 1999; Heske et al., 2004), and we could show that the
toxic potential is indeed linked to the cytosolic fraction of
these mutants. Alternatively, access to the cytosol is possible
via retrograde translocation of PrP out of the ER; this route
has been demonstrated for wild-type PrP and another
pathogenic PrP mutant, D177N (Ma and Lindquist, 2001;
Yedidia et al., 2001). Finally, the generation of transmem-
brane forms of PrP, which is favored by some pathogenic
mutations, leads to the partial exposure of PrP to the cytosol
(reviewed in Hegde et al., 1999). Notably, a quantitative
study of the ultrastructural localization of PrP in mouse
brain revealed that PrP is present in the cytosol in subpopu-
lations of neurons (Mironov et al., 2003).
What might be the mechanism underlying the toxic po-
tential of cytoPrP? Recruitment of anti-apoptotic Bcl-2 to
misfolded PrP provides a plausible explanation for the ob-
served effects. An interaction of PrP and Bcl-2 was described
previously for recombinantly expressed proteins (Kurschner
and Morgan, 1995, 1996). We now show for the first time that
such an interaction can occur in neuronal cells and seems to
be of pathophysiological relevance. First, only PrP mutants
with a toxic potential induced aggregation of Bcl-2. Bcl-2 did
not aggregate in cells expressing mitochondrially localized
PrP or the nontoxic cytosolic PrP mutant cytoPrP116–173.
Second, overexpression of Bcl-2 interfered with cytotoxicity
induced by cytoPrP. Third, Bcl-2202–219, a functionally
active mutant with a deletion in the PrP-interacting domain,
did not coaggregate with cytoPrP, but did interfere with
cytoPrP-induced apoptosis. Fourth, the protective effect of
Hsp70/Hsp40 in cytoPrP-induced toxicity correlated with
their potential to interfere with the recruitment of Bcl-2 into
cytoPrP aggregates. Finally, Bcl-2 adopted a detergent-insol-
uble conformation in scrapie-diseased mouse brain. This
interesting observation might provide a link between prion
propagation and intracellular apoptotic signaling pathways.
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Support for the possibility that PrPSc itself could induce
apoptosis through caspase activation was provided previ-
ously in a cell culture model (Hetz et al., 2003). In addition,
aggresome formation in scrapie-infected cells was shown to
induce caspase-3 activation and apoptosis (Kristiansen et al.,
2005). In this context it is also interesting to note that an
interaction of PrP with NRAGE, another protein involved in
neuronal apoptosis, was reported recently (Bragason and
Palsdottir, 2005).
The exact mechanism by which Bcl-2 exerts its anti-apop-
totic function is not fully understood, but binding to pro-
apoptotic members of the Bcl-2 family seems to be crucial.
Regarding the role of Bcl-2 in cytoPrP-mediated toxicity, two
scenarios are conceivable. Bcl-2 may be inactivated by its
sequestration into cytoPrP aggregates. In support of this
possibility, a recent study revealed that aggregation of Bcl-2
can be of pathophysiological relevance for another neurode-
generative disease. It was shown that the amyotrophic lat-
eral sclerosis (ALS)-associated SOD1 mutant proteins bind
to and aggregate with Bcl-2 (Pasinelli et al., 2004). Alterna-
tively, binding of Bcl-2 to cytoPrP may induce a confor-
mational change of Bcl-2, converting it to a proapoptotic
protein. Evidence for opposing phenotypes of Bcl-2 was
provided by Lin et al. (2004), who showed that the inter-
action with Nurr77 converts Bcl-2 from a protector to a
killer protein.
Our study clearly revealed that PrP-induced toxicity can
be modulated by various cellular factors. Obviously, protea-
somal degradation and chaperone activity have a major
impact on the formation of toxic PrP conformers. To disclose
the cytotoxic potential of cytoPrP, it was necessary to tran-
siently inhibit the proteasome. In untreated cells cytoPrP
was hardly detectable by Western blotting, suggesting that
the main effect of MG132 was to elevate the amount of
cytoPrP. However, it is also conceivable that cells stressed
by proteasomal impairment are sensitized to cytoPrP. Sim-
ilarly, the relative level of Bcl-2 determines whether or not
apoptosis is induced by cytoPrP. Efficiency of the ubiquitin-
proteasome system as well as chaperone activity decrease
with aging, supporting the notion that aged neurons are
particularly vulnerable to the accumulation of misfolded
proteins. In this context, inefficiencies in the signal-se-
quence–mediated translocation of PrP into the ER might
further promote the generation and accumulation of cytosol-
lically localized PrP conformers. This multifaceted influence
on the formation and clearance of cytoPrP, which is highly
dependent on the cellular homeostasis, also provides a plau-
sible explanation for the discrepancy between different re-
ports on the toxic potential of cytosolic PrP (Ma et al., 2002;
Roucou et al., 2003; Rane et al., 2004; Fioriti et al., 2005).
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Hümmer for helpful discussions; and Lindsay A. Smale for critical reading the
manuscript. This work was supported by grants from the Deutsche For-
schungsgemeinschaft (WI 2111/1 and SFB 596), from the Bayerische Sta-
atsminister für Wissenschaft, Forschung, und Kunst (forPrion, MPI3), and
from the Max-Planck-Society.
REFERENCES
Aguzzi, A., and Polymenidou, M. (2004). Mammalian prion biology: one
century of evolving concepts. Cell 116, 313–327.
Bartke, T., Pohl, C., Pyrowolakis, G., and Jentsch, S. (2004). Dual role of
BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase. Mol.
Cell 14, 801–811.
Blochberger, T. C., Cooper, C., Peretz, D., Tatzelt, J., Griffith, O. H., Baldwin,
M. A., and Prusiner, S. B. (1997). Prion protein expression in Chinese hamster
ovary cells using a glutamine synthetase selection and amplification system.
Protein Eng. 10, 1465–1473.
Bragason, B. T., and Palsdottir, A. (2005). Interaction of PrP with NRAGE, a
protein involved in neuronal apoptosis. Mol. Cell. Neurosci. 29, 232–244.
Chesebro, B. (2003). Introduction to the transmissible spongiform encepha-
lopathies or prion diseases. Br. Med. Bull. 66, 1–20.
Chesebro, B. et al. (2005). Anchorless prion protein results in infectious amy-
loid disease without clinical scrapie. Science 308, 1435–1439.
Collinge, J. (2001). Prion diseases of humans and animals: their causes and
molecular basis. Annu. Rev. Neurosci. 24, 519–550.
Danial, N. N., and Korsmeyer, S. J. (2004). Cell death: critical control points.
Cell 116, 205–219.
Fioriti, L., Dossena, S., Stewart, L. R., Stewart, R. S., Harris, D. A., Forloni, G.,
and Chiesa, R. (2005). Cytosolic prion protein (PrP) is not toxic in N2a cells
and primary neurons expressing pathogenic PrP mutations. J. Biol. Chem.
280, 11320–11328.
Hegde, R. S., Mastrianni, J. A., Scott, M. R., DeFea, K. A., Tremblay, P.,
Torchia, M., DeArmond, S. J., Prusiner, S. B., and Lingappa, V. R. (1998). A
transmembrane form of the prion protein in neurodegenerative disease. Sci-
ence 279, 827–834.
Hegde, R. S., Tremblay, P., Groth, D., DeArmond, S. J., Prusiner, S. B., and
Lingappa, V. R. (1999). Transmissible and genetic prion diseases share a
common pathway of neurodegeneration [see comments]. Nature 402, 822–
826.
Heller, U., Winklhofer, K. F., Heske, J., Reintjes, A., and Tatzelt, J. (2003).
Post-translational import of the prion protein into the endoplasmic reticulum
interferes with cell viability: a critical role for the putative transmembrane
domain. J. Biol. Chem. 278, 36139–36147.
Henn, I. H., Gostner, J. M., Tatzelt, J., and Winklhofer, K. F. (2005). Pathogenic
mutations inactivate parkin by distinct mechanisms. J. Neurochem. 92, 114–
122.
Heske, J., Heller, U., Winklhofer, K. F., and Tatzelt, J. (2004). The C-terminal
domain of the prion protein is necessary and sufficient for import into the
endoplasmic reticulum. J. Biol. Chem. 279, 5435–5443.
Hetz, C., Russelakis-Carneiro, M., Maundrell, K., Castilla, J., and Soto, C.
(2003). Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of
pathological prion protein. EMBO J. 22, 5435–5445.
Kascsak, R. J., Rubenstein, R., Merz, P. A., Tonna-DeMasi, M., Fersko, R.,
Carp, R. I., Wisniewski, H. M., and Diringer, H. (1987). Mouse polyclonal and
mAb to scrapie-associated fibril proteins. J. Virol. 61, 3688–3693.
Kim, S., Nollen, E. A., Kitagawa, K., Bindokas, V. P., and Morimoto, R. I.
(2002). Polyglutamine protein aggregates are dynamic. Nat. Cell. Biol. 4,
826–831.
Krasemann, S., Groschup, M. H., Harmeyer, S., Hunsmann, G., and Bodemer,
W. (1996). Generation of monoclonal antibodies against human prion proteins
in PrP0/0 mice. Mol. Med. 2, 725–734.
Kristiansen, M., Messenger, M. J., Klohn, P.C., Brandner, S., Wadsworth, J. D.,
Collinge, J., and Tabrizi, S. J. (2005). Disease-related prion protein forms
aggresomes in neuronal cells leading to caspase-activation and apoptosis.
J. Biol. Chem. Sep 12; Epub ahead of print.
Kurschner, C., and Morgan, J. I. (1995). The cellular prion protein (PrP)
selectively binds to Bcl-2 in the yeast two-hybrid system. Brain Res. Mol.
Brain Res. 30, 165–168.
Kurschner, C., and Morgan, J. I. (1996). Analysis of interaction sites in homo-
and heteromeric complexes containing Bcl-2 family members and the cellular
prion protein. Brain Res. Mol. Brain Res. 37, 249–258.
Lin, B., Kolluri, S. K., Lin, F., Liu, W., Han, Y. H., Cao, X., Dawson, M. I., Reed,
J. C., and Zhang, X. K. (2004). Conversion of Bcl-2 from protector to killer by
interaction with nuclear orphan receptor Nur77/TR3. Cell 116, 527–540.
Ma, J., and Lindquist, S. (2001). Wild-type PrP and a mutant associated with
prion disease are subject to retrograde transport and proteasome degradation.
Proc. Natl. Acad. Sci. USA 98, 14955–14960.
Ma, J., Wollmann, R., and Lindquist, S. (2002). Neurotoxicity and neurode-
generation when PrP accumulates in the cytosol. Science 298, 1781–1785.
Mironov, A. J., Latawiec, D., Wille, H., Bouzamondo-Bernstein, E., Legname,
G., Williamson, R. A., Burton, D., DeArmond, S. J., Prusiner, S. B., and Peters,
P. J. (2003). Cytosolic prion protein in neurons. J. Neurosci. 23, 7183–7193.
Pasinelli, P., Belford, M. E., Lennon, N., Bacskai, B. J., Hyman, B. T., Trott,
I. D., and Brown, R. H. (2004). Amyotrophic lateral sclerosis-associated SOD1
Toxicity of PrP in the Cytosolic Compartment
Vol. 17, August 2006 3367
mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria.
Neuron 43, 19–30.
Prusiner, S. B., Scott, M. R., DeArmond, S. J., and Cohen, F. E. (1998). Prion
protein biology. Cell 93, 337–348.
Rane, N. S., Yonkovich, J. L., and Hegde, R. S. (2004). Protection from cytosolic
prion protein toxicity by modulation of protein translocation. EMBO J. 23,
4550–4559.
Rogers, M., Yehiely, F., Scott, M., and Prusiner, S. B. (1993). Conversion of
truncated and elongated prion proteins into the scrapie isoform in cultured
cells. Proc. Natl. Acad. Sci. USA 90, 3182–3186.
Roucou, X., Guo, Q., Zhang, Y., Goodyer, C. G., and LeBlanc, A. C. (2003).
Cytosolic prion protein is not toxic and protects against Bax-mediated cell
death in human primary neurons. J. Biol. Chem. 278, 40877–40881.
Schultz, J., Schwarz, A., Neidhold, S., Burwinkel, M., Riemer, C., Simon, D.,
Kopf, M., Otto, M., and Baier, M. (2004). Role of interleukin-1 in prion
disease-associated astrocyte activation. Am. J. Pathol. 165, 671–678.
Stan, T., Brix, J., Schneider-Mergener, J., Pfanner, N., Neupert, W., and
Rapaport, D. (2003). Mitochondrial protein import: recognition of internal
import signals of BCS1 by the TOM complex. Mol. Biol. Cell. 23, 2239 –
2250.
Stewart, R. S., Piccardo, P., Ghetti, B., and Harris, D. A. (2005). Neurodegen-
erative illness in transgenic mice expressing a transmembrane form of the
prion protein. J. Neurosci. 25, 3469–3477.
Tatzelt, J., Prusiner, S. B., and Welch, W. J. (1996). Chemical chaperones
interfere with the formation of scrapie prion protein. EMBO J. 15, 6363–6373.
Tatzelt, J., and Winklhofer, K. F. (2004). Folding and misfolding of the prion
protein in the secretory pathway. Amyloid 11, 162–172.
Weissmann, C., Fischer, M., Raeber, A., Büeler, H., Sailer, A., Shmerling, D.,
Rülicke, T., Brandner, S., and Aguzzi, A. (1996). The role of PrP in pathogen-
esis of experimental scrapie. Cold Spring Harb. Symp. Quant. Biol. 61, 511–
522.
Winklhofer, K. F., Heller, U., Reintjes, A., and Tatzelt, J. (2003a). Inhibition of
complex glycosylation increases formation of PrPSc. Traffic 4, 313–322.
Winklhofer, K. F., Henn, I. H., Kay-Jackson, P., Heller, U., and Tatzelt, J.
(2003b). Inactivation of parkin by oxidative stress and C-terminal truncations;
a protective role of molecular chaperones. J. Biol. Chem. 278, 47199–47208.
Winklhofer, K. F., Heske, J., Heller, U., Reintjes, A., Muranji, W., Moarefi, I.,
and Tatzelt, J. (2003c). Determinants of the in vivo-folding of the prion
protein: a bipartite function of helix 1 in folding and aggregation. J. Biol.
Chem. 278, 14961–14970.
Winklhofer, K. F., and Tatzelt, J. (2000). Cationic lipopolyamines induce
degradation of PrPSc in scrapie-infected mouse neuroblastoma cells. Biol.
Chem. 381, 463–469.
Winklhofer, K. F., and Tatzelt, J. (2006). The role of chaperones in Parkinson’s
disease and prion diseases. In: Molecular Chaperones in Health and Diseases,
Vol. 172, ed. M. Gaestel, New York: Springer-Verlag, 221–258.
Yedidia, Y., Horonchik, L., Tzaban, S., Yanai, A., and Taraboulos, A. (2001).
Proteasomes and ubiquitin are involved in the turnover of the wild-type prion
protein. EMBO J. 20, 5383–5391.
Yost, C. S., Lopez, C. D., Prusiner, S. B., Myers, R. M., and Lingappa, V. R.
(1990). Non-hydrophobic extracytoplasmic determinant of stop transfer in the
prion protein. Nature 343, 669–672.
Zanusso, G., Petersen, R. B., Jin, T., Jing, Y., Kanoush, R., Ferrari, S., Gambetti,
P., and Singh, N. (1999). Proteasomal degradation and N-terminal protease
resistance of the codon 145 mutant prion protein. J. Biol. Chem. 274, 23396–
23404.
A. S. Rambold et al.
Molecular Biology of the Cell3368
